ArticleArchives of disease in childhood2025
21-deoxycortisol as a second-tier test in congenital adrenal hyperplasia newborn screening in The Netherlands: two-year evaluation.
Article in Archives of disease in childhood, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- 21-Deoxycortisone: A Novel Sensitive and Specific Newborn Screening Marker for Congenital Adrenal Hyperplasia.International journal of neonatal screening · 2026Article
- Current insights into monitoring of congenital adrenal hyperplasia.Frontiers in endocrinology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveCongenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency is an inherited adrenal steroid synthesis disorder included in Dutch newborn screening (NBS) since 2002. Screening involves measuring 17-hydroxyprogesterone (17-OHP) in dried blood spots (DBS) with gestational age-adjusted cut-offs. Since October 2021, a second-tier 21-deoxycortisol (21-DF) test has replaced the 17-OHP measurement in a second heel prick after inconclusive results. This study evaluates the performance of the second-tier test from 1 October 2021 to 30 September 2023.
design17-OHP was measured by immunoassay in regional NBS laboratories. DBS with inconclusive and positive 17-OHP results was sent to Amsterdam UMC for 21-DF measurement by liquid chromatography tandem mass spectrometry. Genetic analysis of
resultsOver 2 years, 21-DF was measured in DBS of 147 newborns (=0.04%). Twenty newborns were directly referred to a paediatric endocrinologist based on positive 17-OHP results: 15 had a positive 21-DF and were diagnosed with classical CAH (genetically confirmed), while five were first-tier false-positives. Of 127 newborns with inconclusive 17-OHP results, three had a positive 21-DF and were referred but not diagnosed with CAH: second-tier false-positives. In total, 8/23 referred newborns were false-positives. Genetic analysis of six false-positive second-tier DBS showed pathogenic
conclusionsThe modified protocol improved CAH screening by preventing 127 heel pricks in 2 years and reducing unnecessary referrals (currently 2.4%, previously 7.7%). 5/6 false-positive second-tier tests were most likely due to non-classical CAH. Further optimisation of cut-offs may prevent these false-positives.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.